Get the Stockscreener App
2.51
4.92%
-0.13
Gain Therapeutics Inc stock is traded at $2.51, with a volume of 263.80K.
It is down -4.92% in the last 24 hours and up +10.57% over the past month.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
See More
Previous Close:
$2.64
Open:
$2.68
24h Volume:
263.80K
Relative Volume:
1.11
Market Cap:
$70.03M
Revenue:
$210.70K
Net Income/Loss:
$-21.37M
P/E Ratio:
-2.2818
EPS:
-1.1
Net Cash Flow:
$-21.10M
1W Performance:
+17.84%
1M Performance:
+10.57%
6M Performance:
+163.52%
1Y Performance:
-47.16%
1-Day Range:
$2.4346
$2.75
1-Week Range:
$1.975
$2.75
52-Week Range:
$0.89
$5.30
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
2.51 | 70.03M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.56 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.92 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.86 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.81 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.13 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
Sacks Parente Golf Inc (NASDAQ: SPGC): Can The Stock Still Lose Despite An 38.15% YTD Gain? - Marketing Sentinel
Gain Therapeutics Advances GT-02287 in Parkinson’s Trials - TipRanks
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update - citybiz
Travere Therapeutics Inc (TVTX) deserves deeper analysis - US Post News
Are Corcept Therapeutics Inc’shares a good deal? - US Post News
Parkinson's Breakthrough: New Drug Shows 53% Enzyme Boost, Phase 1b Trial Launching - StockTitan
Spero Therapeutics Inc (SPRO)’s results reveal risk - US Post News
Gain Therapeutics (NASDAQ:GANX) Shares Up 10.4% – What’s Next? - Defense World
Viridian Therapeutics Inc (VRDN)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Market Insights: Avidity Biosciences Inc (RNA)’s Notable Gain of 4.32, Closing at 33.34 - The Dwinnex
Gain Therapeutics To Participate in Upcoming Investor Conferences - The Manila Times
Gain Therapeutics, Inc. Announces Upcoming Presentations at BIO CEO & Investor Conference and Oppenheimer 35th Annual Healthcare Life Sciences Conference - Nasdaq
Biotech Spotlight: Gain Therapeutics Takes Center Stage at Two Major Investor Conferences - StockTitan
Have you been able to find a good deal on Capricor Therapeutics Inc’s shares? - US Post News
Closing Figures Unveiled: Canada Goose Holdings Inc (GOOS) Gain 1.05, Closes at 10.57 - The Dwinnex
4D Molecular Therapeutics Inc (FDMT) deserves deeper analysis - US Post News
Are Stoke Therapeutics Inc (STOK) shares a good deal now? - US Post News
Spyre Therapeutics Inc (SYRE) stock analysis: A comprehensive overview - US Post News
Should investors be concerned about Unicycive Therapeutics Inc (UNCY)? - US Post News
Is Tenaya Therapeutics Inc (TNYA) a good investment opportunity? - US Post News
Closing Figures Unveiled: Ondas Holdings Inc (ONDS) Gain 3.55, Closes at 1.75 - The Dwinnex
Stock summary: Cyclerion Therapeutics surged by 41.01% over the past five days - Business Upturn
Amentum Holdings Inc (AMTM) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Investors in Beam Therapeutics (NASDAQ:BEAM) from three years ago are still down 55%, even after 3.8% gain this past week - Yahoo Finance
Takeda makes waves again with CEO pick - BioCentury
UiPath Inc (PATH) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Medicare Advantage Members Gain Access to Innovative Digital Therapeutics Through New Partnership - Yahoo Finance
Sector Update: Health Care Stocks Gain Late Afternoon -January 27, 2025 at 04:04 pm EST - Marketscreener.com
Nvidia Shares Tumbles as Japanese Rivals Gain Ground in AI Chips - Yahoo Finance
This Weight-Loss Drug Stock Could Gain 200%, Challenge Novo Nordisk, Eli Lilly. - Barron's
Investors in Seres Therapeutics (NASDAQ:MCRB) from three years ago are still down 88%, even after 17% gain this past week - Simply Wall St
Vir, Sana gain new modality POC: BioCentury’s Clinical Report - BioCentury
Improved Revenues Required Before Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock's 30% Jump Looks Justified - Simply Wall St
Will CRL Stock Gain From Integration of Akron Bio's CSS Product Line? - Yahoo Finance
Perrigo cut to Hold at Argus on topline risks - MSN
Regions Financial Q4 2024 Earnings Preview - MSN
All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy - MSN
Gain Therapeutics regains compliance with Nasdaq listing By Investing.com - Investing.com South Africa
Gain Therapeutics regains compliance with Nasdaq listing - Investing.com India
Parkinson's Disease Clinical and Non-Clinical Studies, Key - openPR
Stock market today: Eterna Therapeutics gain over 136.63% while Phio Pharmaceuticals plunged by 40.25% in early trading - Business Upturn
Geode Capital Management LLC Has $484,000 Stock Holdings in Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
Coinbase Global Inc (COIN) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Best Momentum Stocks to Buy for January 9th - Yahoo Finance
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287 - The Manila Times
Gain Therapeutics Forms Elite Advisory Board to Accelerate Parkinson's Drug Development - StockTitan
Gain Therapeutics (GANX) Shares Rise In After-Hour Trading - Stocks Telegraph
Gain Therapeutics Appoints New CEO Amidst Clinical Progress - TipRanks
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer - Marketscreener.com
Gain Therapeutics appoints new CEO and finance SVP - Investing.com
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gain Therapeutics Inc Stock (GANX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Islam Khalid | Executive Chairman |
Aug 09 '24 |
Buy |
1.00 |
50,000 |
49,940 |
50,000 |
| RICHMAN ERIC I | Director |
Jul 01 '24 |
Buy |
1.22 |
17,000 |
20,670 |
289,629 |
| Riley Jeffrey Scott | Director |
Mar 28 '24 |
Buy |
3.86 |
30,000 |
115,770 |
30,000 |
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):